Immune microenvironment composition in non‐small cell lung cancer and its association with survival. Issue 6 (12th June 2020)
- Record Type:
- Journal Article
- Title:
- Immune microenvironment composition in non‐small cell lung cancer and its association with survival. Issue 6 (12th June 2020)
- Main Title:
- Immune microenvironment composition in non‐small cell lung cancer and its association with survival
- Authors:
- Tamminga, Menno
Hiltermann, Thijo Jeroen N
Schuuring, Ed
Timens, Wim
Fehrmann, Rudolf SN
Groen, Harry JM - Abstract:
- Abstract: Objectives: In non‐small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In this in silico study, the immune infiltrate composition in NSCLC patients was evaluated. Methods: Gene expression data of tumors from early NSCLC patients were obtained from Gene Expression Omnibus (GEO). With CIBERSORT, 22 immune cell fractions were estimated. Results: The immune infiltrate of 1430 pretreatment NSCLC patients contained mostly plasma cells, macrophages and CD8 T cells. Higher fractions of resting mast and CD4 T‐helper cells were associated with longer overall survival (OS) (HR = 0.95, P < 0.01; HR = 0.98, = 0.04, respectively) and higher fractions of M2 macrophages and active dendritic cells with shorter survival (HR = 1.02, P = 0.03; HR = 1.03, P = 0.05, respectively). Adenocarcinoma patients with survival data ( n = 587) showed higher fractions of resting mast and resting CD4 T cells, and lower M0 macrophages than squamous cell carcinoma ( n = 254), which were associated with OS (HR = 0.95, P = 0.04; HR = 0.97, P = 0.01; HR = 1.03, P = 0.01, respectively). Fractions of memory B cells, naïve CD4 T cells and neutrophils had different associations with survival depending on the subtype. Smokers had had higher fractions of regulatory T cell, follicular helper T cell, neutrophil and M2 macrophage, which were associated with shorter survival (HR = 1.3, P < 0.01; HR = 1.13, P = 0.02; HR = 1.09, P = 0.03; HR = 1.04, P = 0.02,Abstract: Objectives: In non‐small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In this in silico study, the immune infiltrate composition in NSCLC patients was evaluated. Methods: Gene expression data of tumors from early NSCLC patients were obtained from Gene Expression Omnibus (GEO). With CIBERSORT, 22 immune cell fractions were estimated. Results: The immune infiltrate of 1430 pretreatment NSCLC patients contained mostly plasma cells, macrophages and CD8 T cells. Higher fractions of resting mast and CD4 T‐helper cells were associated with longer overall survival (OS) (HR = 0.95, P < 0.01; HR = 0.98, = 0.04, respectively) and higher fractions of M2 macrophages and active dendritic cells with shorter survival (HR = 1.02, P = 0.03; HR = 1.03, P = 0.05, respectively). Adenocarcinoma patients with survival data ( n = 587) showed higher fractions of resting mast and resting CD4 T cells, and lower M0 macrophages than squamous cell carcinoma ( n = 254), which were associated with OS (HR = 0.95, P = 0.04; HR = 0.97, P = 0.01; HR = 1.03, P = 0.01, respectively). Fractions of memory B cells, naïve CD4 T cells and neutrophils had different associations with survival depending on the subtype. Smokers had had higher fractions of regulatory T cell, follicular helper T cell, neutrophil and M2 macrophage, which were associated with shorter survival (HR = 1.3, P < 0.01; HR = 1.13, P = 0.02; HR = 1.09, P = 0.03; HR = 1.04, P = 0.02, respectively). Conclusion: Pretreatment differences in immune cell composition in NSCLC are associated with survival and depend on smoking status and histological subtype. Smokers' immune composition is associated with lower survival. Abstract : Because of small populations, it is difficult to assess differences in the immunocomposition and their associated survival depending on smoking behaviour and tumor subtype for non‐small cell lung cancer patients. Here, we used an in silico approach of all available material to identify these differences and the associations with survival. Immune cell fractions showed different, sometimes opposing associations depending on the tumor subtype and smoking status. … (more)
- Is Part Of:
- Clinical & translational immunology. Volume 9:Issue 6(2020)
- Journal:
- Clinical & translational immunology
- Issue:
- Volume 9:Issue 6(2020)
- Issue Display:
- Volume 9, Issue 6 (2020)
- Year:
- 2020
- Volume:
- 9
- Issue:
- 6
- Issue Sort Value:
- 2020-0009-0006-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-06-12
- Subjects:
- adenocarcinoma -- biostatistics -- immune microenvironment -- non‐small cell lung cancer -- smoking -- squamous cell carcinoma
Immunologic diseases -- Periodicals
Immunology -- Periodicals
Clinical medicine -- Periodicals
Immune System Diseases -- therapy
Immunotherapy
Immunologic Factors -- therapeutic use
Translational Medical Research
Molecular Targeted Therapy
Clinical medicine
Immunologic diseases
Immunology
Periodicals
Periodicals
Fulltext
Internet Resources
Periodicals
616.079 - Journal URLs:
- http://www.nature.com/cti/index.html ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/2610/ ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0068 ↗
http://www.nature.com/ ↗
http://www.nature.com/cti/index.html ↗ - DOI:
- 10.1002/cti2.1142 ↗
- Languages:
- English
- ISSNs:
- 2050-0068
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13354.xml